Subcutaneous injection: learning from experience in other specialties

Open access


Haemophilia treatment is characterised by intravenous infusions of clotting factor concentrates, with nurses frequently taking the lead role in administration, patient training and patient care. In recent years, a number of novel factor and non-factor-based therapies delivered by subcutaneous injection have been developed. These therapies are now undergoing clinical trials and will shortly be available in clinical practice. The coming era of at least some haemophilia treatments being delivered by subcutaneous injection clearly represents a significant change not only for patients (for whom they may be more convenient) but also for haemophilia nurse practice, particularly with respect to bleed and surgical management plans, and hence for nurse training and education. This review describes evidence-based guidance on subcutaneous injection technique and summarises the implications for nurses.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Richards M Williams M Chalmers E et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010; 149: 498-507.

  • 2. Berntorp E Dolan G Hay C et al. European retrospective study of real-life haemophilia treatment. Haemophilia 2017; 23: 105-14.

  • 3. Collins P Chalmers E Chowdary P et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia 2016; 22: 487-98.

  • 4. Oldenburg J Mahlangu JN Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809-18.

  • 5. Pasi KJ Rangarajan S Georgiev P et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377: 819-28.

  • 6. Hacker MR Geraghty S Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.

  • 7. Shaw D Riley GA. The impact on parents of developments in the care of children with bleeding disorders. Haemophilia 2008; 14: 65-7.

  • 8. Furmedge J Lima S Monagle P et al. 'I don't want to hurt him.' Parents' experiences of learning to administer clotting factor to their child. Haemophilia 2013; 19: 206-11.

  • 9. World Health Organisation. WHO best practices for injections and related procedures toolkit. 2010. Available from (accessed 16 April 2018).

  • 10. Frid AH Kreugel G Grassi G et al. New insulin delivery recommendations. Mayo Clin Proc 2016; 91: 1231-55.

  • 11. FIT UK Forum for Injection Technique UK. The UK Injection and Infusion Technique Recommendations 4th edn. October 2016. Available from (accessed 16 April 2018).

  • 12. The Royal Marsden NHS Foundation Trust. The Royal Marsden Manual of Clinical Nursing Procedures 9th edn 2015. Available from (accessed 16 April 2018).

  • 13. FIT4Safety. Injection Safety in UK and Ireland; Safety of Sharps in Diabetes Recommendations 1st edn. 2012. Available from (accessed 16 April 2018).

  • 14. Costigliola V Frid A Letondeur C et al. Needlestick injuries in European nurses in diabetes. Diabetes Metab 2012; 38 Suppl 1: S9-14.

  • 15. Tandon N Kalra S Balhara YPS et al. Forum for injection technique and therapy expert recommendations India: the Indian recommendations for best practice in insulin injection technique 2017. Indian J Endocrinol Metab 2017; 21: 600-17.

  • 16. Ogston-Tuck S. Subcutaneous injection technique: an evidence-based approach. Nurs Stand 2014; 29: 53-8.

  • 17. Desplats M Pascart T Jelin G et al. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol 2017; 36: 1395-1400.

  • 18. Chilton F Collett RA. Treatment choices preferences and decision-making by patients with rheumatoid arthritis. Musculoskelet Care 2008; 6: 1-14.

  • 19. Huynh TK Ostergaard A Egsmose C et al. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence 2014; 8: 93-9.

  • 20. Bolge SC Eldridge HM Lofland JH et al. Patient experience with intravenous biologic therapies for ankylosing spondylitis Crohn's disease psoriatic arthritis psoriasis rheumatoid arthritis and ulcerative colitis. Patient Prefer Adherence 2017; 11: 661-9.

  • 21. Sylwestrzak G Liu J Stephenson JJ et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits 2014; 7: 71-81.

  • 22. Allen PB Lindsay H Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol 2010; 10:1. doi: 10.1186/1471-230X-10-1.

  • 23. Pivot X Gligorov J Muller V et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol 2013; 14: 962-70.

  • 24. Jackisch C Muller V Dall P et al. Subcutaneous trastuzumab for HER2-positive breast cancer - evidence and practical experience in 7 German centers. Geburtshilfe Frauenheilkd 2015; 75: 566-73.

  • 25. Beer K Muller M Hew-Winzeler AM et al. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BMC Neurol 2011; 11: 144.

  • 26. Stoner KL Harder H Fallowfield LJ et al. Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient 2015; 8: 145-53.

  • 27. Jin JF Zhu LL Chen M et al. The optimal choice of medication administration route regarding intravenous intramuscular and subcutaneous injection. Patient Prefer Adherence 2015; 9: 923-42.

  • 28. Ponzetti C Canciani M Farina M et al. Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach. Clinicoecon Outcomes Res 2016; 8: 353-9.

  • 29. Carlson J Cox K Bedwell K et al. Rituximab for subcutaneous delivery: clinical management principles from a nursing perspective. Int J Nurs Pract 2015; 21 Suppl 3: 1-13.

  • 30. Rule S Collins GP Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ 2014; 17: 459-68.

  • 31. Barbee MS Harvey RD Lonial S et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother 2013; 47: 1136-42.

Journal information
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 951 795 45
PDF Downloads 450 380 20